Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group

Yousif Matloub, Bruce C. Bostrom, Stephen P. Hunger, Linda Stork, Anne Angiolillo, Harland Sather, Mei La, Julie M. Gastier-Foster, Nyla A. Heerema, Scott Sailer, Patrick J. Buckley, Blythe Thomson, Catherine Cole, James B. Nachman, Gregory Reaman, Naomi Winick, William L. Carroll, Meenakshi Devidas, Paul S. Gaynon

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Children's Cancer Group-1991 selected 2 components from the Children's Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.

Original languageEnglish (US)
Pages (from-to)243-251
Number of pages9
JournalBlood
Volume118
Issue number2
DOIs
StatePublished - Jul 14 2011

Fingerprint

Oncology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Disease-Free Survival
Vincristine
6-Mercaptopurine
Maintenance
Dexamethasone
Survival
Leucovorin
National Cancer Institute (U.S.)
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia : A report from the Children's Oncology Group. / Matloub, Yousif; Bostrom, Bruce C.; Hunger, Stephen P.; Stork, Linda; Angiolillo, Anne; Sather, Harland; La, Mei; Gastier-Foster, Julie M.; Heerema, Nyla A.; Sailer, Scott; Buckley, Patrick J.; Thomson, Blythe; Cole, Catherine; Nachman, James B.; Reaman, Gregory; Winick, Naomi; Carroll, William L.; Devidas, Meenakshi; Gaynon, Paul S.

In: Blood, Vol. 118, No. 2, 14.07.2011, p. 243-251.

Research output: Contribution to journalArticle

Matloub, Y, Bostrom, BC, Hunger, SP, Stork, L, Angiolillo, A, Sather, H, La, M, Gastier-Foster, JM, Heerema, NA, Sailer, S, Buckley, PJ, Thomson, B, Cole, C, Nachman, JB, Reaman, G, Winick, N, Carroll, WL, Devidas, M & Gaynon, PS 2011, 'Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group', Blood, vol. 118, no. 2, pp. 243-251. https://doi.org/10.1182/blood-2010-12-322909
Matloub, Yousif ; Bostrom, Bruce C. ; Hunger, Stephen P. ; Stork, Linda ; Angiolillo, Anne ; Sather, Harland ; La, Mei ; Gastier-Foster, Julie M. ; Heerema, Nyla A. ; Sailer, Scott ; Buckley, Patrick J. ; Thomson, Blythe ; Cole, Catherine ; Nachman, James B. ; Reaman, Gregory ; Winick, Naomi ; Carroll, William L. ; Devidas, Meenakshi ; Gaynon, Paul S. / Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia : A report from the Children's Oncology Group. In: Blood. 2011 ; Vol. 118, No. 2. pp. 243-251.
@article{a6141e6e6e2d401a9fb668b803723ab8,
title = "Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group",
abstract = "Children's Cancer Group-1991 selected 2 components from the Children's Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7{\%} ± 1.4{\%} and 96{\%} ± 0.9{\%} versus 92.6{\%} ± 1.2{\%} and 96.5{\%} ± 0.8{\%} for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9{\%} ± 1.3{\%} and 97.1{\%} ± 0.8{\%} versus 90.5{\%} ± 1.3{\%} and 95.4{\%} ± 3.8{\%} for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.",
author = "Yousif Matloub and Bostrom, {Bruce C.} and Hunger, {Stephen P.} and Linda Stork and Anne Angiolillo and Harland Sather and Mei La and Gastier-Foster, {Julie M.} and Heerema, {Nyla A.} and Scott Sailer and Buckley, {Patrick J.} and Blythe Thomson and Catherine Cole and Nachman, {James B.} and Gregory Reaman and Naomi Winick and Carroll, {William L.} and Meenakshi Devidas and Gaynon, {Paul S.}",
year = "2011",
month = "7",
day = "14",
doi = "10.1182/blood-2010-12-322909",
language = "English (US)",
volume = "118",
pages = "243--251",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia

T2 - A report from the Children's Oncology Group

AU - Matloub, Yousif

AU - Bostrom, Bruce C.

AU - Hunger, Stephen P.

AU - Stork, Linda

AU - Angiolillo, Anne

AU - Sather, Harland

AU - La, Mei

AU - Gastier-Foster, Julie M.

AU - Heerema, Nyla A.

AU - Sailer, Scott

AU - Buckley, Patrick J.

AU - Thomson, Blythe

AU - Cole, Catherine

AU - Nachman, James B.

AU - Reaman, Gregory

AU - Winick, Naomi

AU - Carroll, William L.

AU - Devidas, Meenakshi

AU - Gaynon, Paul S.

PY - 2011/7/14

Y1 - 2011/7/14

N2 - Children's Cancer Group-1991 selected 2 components from the Children's Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.

AB - Children's Cancer Group-1991 selected 2 components from the Children's Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.

UR - http://www.scopus.com/inward/record.url?scp=79960462879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960462879&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-12-322909

DO - 10.1182/blood-2010-12-322909

M3 - Article

C2 - 21562038

AN - SCOPUS:79960462879

VL - 118

SP - 243

EP - 251

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -